Celyad Oncology SA
CYAD
Company Profile
Business description
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks, including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments. It generates the majority of its revenue from the Cardiology segment.
Contact
Rue Edouard Belin 2
Axis Business Park
Brabant Wallon
Mont-Saint-Guibert1435
BELT: +32 10394100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
39
Stocks News & Analysis
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
Investors please with latest results.
stocks
Why doesn’t the market like the earnings from this US tech giant?
Good quarter with AI demand ramping.
stocks
Our Tesla fair value increases meaningfully
Progress on Robotaxi and Optimus shows real world AI growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.80 | 94.40 | -1.02% |
| CAC 40 | 8,136.42 | 65.06 | 0.81% |
| DAX 40 | 24,567.52 | 258.06 | 1.06% |
| Dow JONES (US) | 49,071.56 | 55.96 | 0.11% |
| FTSE 100 | 10,223.59 | 51.83 | 0.51% |
| HKSE | 27,387.11 | 580.98 | -2.08% |
| NASDAQ | 23,685.12 | 172.33 | -0.72% |
| Nikkei 225 | 53,322.85 | 52.75 | -0.10% |
| NZX 50 Index | 13,423.18 | 74.57 | 0.56% |
| S&P 500 | 6,969.01 | 9.02 | -0.13% |
| S&P/ASX 200 | 8,869.10 | 86.00 | -0.96% |
| SSE Composite Index | 4,117.95 | 40.04 | -0.96% |